KRYS – Krystal Biotech, Inc.
KRYS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.06
Margin Of Safety %
-16
Put/Call OI Ratio
0.23
EPS Next Q Diff
0.36
EPS Last/This Y
1.3
EPS This/Next Y
1.7
Price
299.26
Target Price
330.56
Analyst Recom
1.17
Performance Q
9.05
Upside
-12.6%
Beta
0.51
Ticker: KRYS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | KRYS | 267.9 | 0.69 | 0.05 | 5137 |
| 2026-04-24 | KRYS | 272.1 | 0.69 | 0.64 | 5141 |
| 2026-04-27 | KRYS | 272.87 | 0.69 | 0.08 | 5133 |
| 2026-04-28 | KRYS | 269.23 | 0.69 | 1.20 | 5139 |
| 2026-04-29 | KRYS | 259.64 | 0.69 | 0.35 | 5146 |
| 2026-04-30 | KRYS | 262.2 | 0.69 | 0.40 | 5159 |
| 2026-05-01 | KRYS | 265.66 | 0.69 | 7.64 | 5164 |
| 2026-05-04 | KRYS | 285.06 | 0.79 | 4.98 | 5517 |
| 2026-05-05 | KRYS | 284.29 | 0.74 | 0.11 | 5407 |
| 2026-05-06 | KRYS | 288.99 | 0.65 | 0.07 | 5855 |
| 2026-05-07 | KRYS | 296.95 | 0.64 | 0.24 | 5941 |
| 2026-05-08 | KRYS | 305.99 | 0.63 | 0.38 | 6090 |
| 2026-05-11 | KRYS | 313.07 | 0.64 | 0.17 | 6278 |
| 2026-05-12 | KRYS | 309.85 | 0.62 | 0.04 | 6452 |
| 2026-05-13 | KRYS | 312.34 | 0.62 | 0.49 | 6496 |
| 2026-05-14 | KRYS | 316.49 | 0.63 | 0.00 | 6655 |
| 2026-05-15 | KRYS | 306.46 | 0.58 | 0.26 | 7030 |
| 2026-05-18 | KRYS | 291.74 | 0.16 | 0.88 | 3031 |
| 2026-05-19 | KRYS | 293.66 | 0.19 | 0.26 | 3116 |
| 2026-05-20 | KRYS | 301.97 | 0.19 | 0.25 | 3122 |
| 2026-05-21 | KRYS | 304.38 | 0.19 | 5.00 | 3148 |
| 2026-05-22 | KRYS | 299.28 | 0.23 | 0.11 | 3249 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | KRYS | 267.93 | 20.5 | 46.1 | 7.74 |
| 2026-04-24 | KRYS | 272.52 | 20.5 | 57.5 | 7.74 |
| 2026-04-27 | KRYS | 272.65 | 18.2 | 53.3 | 7.57 |
| 2026-04-28 | KRYS | 269.52 | 18.2 | 50.4 | 7.57 |
| 2026-04-30 | KRYS | 262.35 | 18.2 | 55.7 | 7.57 |
| 2026-05-01 | KRYS | 265.85 | 18.2 | 56.5 | 7.57 |
| 2026-05-04 | KRYS | 286.58 | 18.2 | 71.7 | 7.57 |
| 2026-05-05 | KRYS | 284.52 | 18.2 | 51.1 | 7.57 |
| 2026-05-06 | KRYS | 288.80 | 18.2 | 56.7 | 7.57 |
| 2026-05-07 | KRYS | 296.57 | 34.3 | 48.0 | 7.76 |
| 2026-05-08 | KRYS | 305.83 | 34.3 | 49.2 | 7.76 |
| 2026-05-11 | KRYS | 312.88 | 34.0 | 47.1 | 7.69 |
| 2026-05-12 | KRYS | 309.76 | 50.5 | 39.2 | 8.51 |
| 2026-05-13 | KRYS | 312.61 | 50.5 | 43.4 | 8.51 |
| 2026-05-14 | KRYS | 316.20 | 50.5 | 44.4 | 8.51 |
| 2026-05-15 | KRYS | 306.47 | 50.5 | 33.7 | 8.51 |
| 2026-05-18 | KRYS | 291.24 | 50.5 | 29.7 | 8.38 |
| 2026-05-19 | KRYS | 293.30 | 50.5 | 43.3 | 8.38 |
| 2026-05-20 | KRYS | 302.04 | 50.5 | 48.5 | 8.38 |
| 2026-05-21 | KRYS | 304.29 | 50.5 | 43.4 | 8.38 |
| 2026-05-22 | KRYS | 299.26 | 50.5 | 37.5 | 8.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | KRYS | -6.08 | -1.32 | 12.30 |
| 2026-04-24 | KRYS | -6.08 | -1.32 | 12.30 |
| 2026-04-27 | KRYS | -6.08 | -1.59 | 11.39 |
| 2026-04-28 | KRYS | -6.19 | -1.59 | 11.39 |
| 2026-04-29 | KRYS | -6.19 | -1.59 | 11.39 |
| 2026-04-30 | KRYS | -6.19 | -1.59 | 11.39 |
| 2026-05-01 | KRYS | -6.19 | -1.59 | 11.39 |
| 2026-05-04 | KRYS | -6.19 | -1.34 | 11.39 |
| 2026-05-05 | KRYS | -6.19 | -1.34 | 11.39 |
| 2026-05-06 | KRYS | -6.19 | -1.34 | 11.39 |
| 2026-05-07 | KRYS | -6.18 | -1.34 | 11.37 |
| 2026-05-08 | KRYS | -6.18 | -1.34 | 11.37 |
| 2026-05-11 | KRYS | -6.18 | -1.47 | 11.37 |
| 2026-05-12 | KRYS | -6.18 | -1.47 | 12.08 |
| 2026-05-13 | KRYS | -6.18 | -1.47 | 12.08 |
| 2026-05-14 | KRYS | -6.18 | -1.47 | 12.08 |
| 2026-05-15 | KRYS | -6.18 | -1.47 | 12.08 |
| 2026-05-18 | KRYS | -6.18 | -1.99 | 12.06 |
| 2026-05-19 | KRYS | -6.24 | -1.99 | 12.06 |
| 2026-05-20 | KRYS | -6.24 | -1.99 | 12.06 |
| 2026-05-21 | KRYS | -6.24 | -1.99 | 12.06 |
| 2026-05-22 | KRYS | -6.24 | -1.99 | 12.06 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.83
Avg. EPS Est. Current Quarter
1.94
Avg. EPS Est. Next Quarter
2.19
Insider Transactions
-6.24
Institutional Transactions
-1.99
Beta
0.51
Average Sales Estimate Current Quarter
125
Average Sales Estimate Next Quarter
137
Fair Value
252.73
Quality Score
90
Growth Score
39
Sentiment Score
32
Actual DrawDown %
6.3
Max Drawdown 5-Year %
-44.5
Target Price
330.56
P/E
40.03
Forward P/E
30.84
PEG
1.33
P/S
21.15
P/B
6.9
P/Free Cash Flow
37.19
EPS
7.48
Average EPS Est. Cur. Y
8.38
EPS Next Y. (Est.)
10.08
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
53.92
Relative Volume
0.57
Return on Equity vs Sector %
-9.4
Return on Equity vs Industry %
6.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.64
EBIT Estimation
37.5
◆
KRYS
Healthcare
$299.45
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
56.6
Range 1M
69.5%
Sup Dist
0.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
13.3%
EPS NY
25.3%
52W%
89.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+6.3% upside
Upside
+6.3%
Quality
90
MoS
-16%
Krystal Biotech, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 295
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
KRYS
Latest News
—
Caricamento notizie per KRYS…
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading